Chadi Hage Chehade

PGY1 @UofUInternalMed
Former Post-Doctoral Research Fellow @Huntsmancancer @UUtah 🇺🇸
MD 23' @usjliban
🇱🇧🇫🇷

[Umang Swami, MD, MSCI, FASCO @umangtalking]

Huge congratulations to my mentor and friend @neerajaiims on his election to the @ASCO Nominating Committee. A true leader whose humility, vision, and mentorship continue to inspire so many. @OncoAlert https://t.co/65SdS1eUW7

[UroToday.com @urotoday]

Delayed genomic testing limits access to life-prolonging cancer treatments. @chadihcmd @huntsmancancer joins @neerajaiims to discuss the utilization of next-generation sequencing in nearly 200,000 patients with common cancers having approved targeted therapies. #WatchNow on UroToday > https://t.co/PL7OXCP8sh

[Umang Swami, MD, MSCI, FASCO @umangtalking]

Thrilled for Day 2 of invigorating discussions on prostate and renal cell cancer at #UromigosLive! by @tompowles1 @brian_rini @Uromigos @OncoAlert @urotoday

[Umang Swami, MD, MSCI, FASCO @umangtalking]

Excited to be part of @Uromigos LIVE & UnpluggD ‘25! Can’t wait for the lively, engaging, unfiltered, and insightful conversations that make this meeting so special @OncoAlert

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit https://t.co/4riSVk7AQy to learn more about the candidates and place your vote! Thank you!!

[Umang Swami, MD, MSCI, FASCO @umangtalking]

Proud to endorse my mentor and friend @neerajaiims for the @ASCO Nominating Committee! His humility, kindness, unwavering dedication to mentoring young investigators globally & advancing cancer research inspire me every day. A true leader who lifts everyone around him.

[UroToday.com @urotoday]

Delayed genomic testing limits access to life-prolonging cancer treatments. @chadihcmd @huntsmancancer joins @neerajaiims to discuss the utilization of next-generation sequencing in nearly 200,000 patients with common cancers having approved targeted therapies. #WatchNow on UroToday > https://t.co/PL7OXCP8sh

[Yüksel Ürün @DrYukselUrun]

Thank you Neeraj for reminding us of the importance of accessibility in NGS testing for metastatic prostate cancer. Equity must guide innovation. #IUCS25 @chadihcmd
@urologysummit @gbanna74 @ravikanesvaran @OncoAlert @ONCOassist @neerajaiims @PGrivasMDPhD @drenriquegrande @montypal @nataliagandur @alison_tree @ManiamAkash @Ecastromarcos @huntsmancancer

[UroToday.com @urotoday]

Delayed genomic testing limits access to life-prolonging cancer treatments. @chadihcmd @huntsmancancer joins @neerajaiims to discuss the utilization of next-generation sequencing in nearly 200,000 patients with common cancers having approved targeted therapies. #WatchNow on UroToday > https://t.co/PL7OXCP8sh

[University of Utah Department of Internal Medicine @UofUInternalMed]

Congrats to Dr. Chadi Hage Chehade on presenting at #ASCO25 on the timing and use of tumor next-generation sequencing testing for the 5 most common cancers in the U.S., and receiving the Conquer Cancer Merit Award! Check out his interview with @urotoday: https://t.co/AlSHVz6po9

[Open Medicine Insights @OpenMedInsights]

🌟🌎 #GlobalGUFriday
🧬 PARP inhibitors: from ovarian cancer to a pan-tumor approach — Landmark phase III trials transforming care in HRR-mutated tumors.
@chadihcmd @ggebraelmd @nsayeghmd @ziremozay @SWOGadvocate
@JenniferLitton @umangtalking
@neerajaiims

📌 FDA/EMA approvals based on pivotal data:

🟣 Ovary – SOLO-1/2, PRIMA, PAOLA-1, ARIEL3 (maintenance & 1L combo)
🩷 Breast – OlympiA, EMBRACA (gBRCA early & metastatic)
🟡 Prostate – PROfound, PROpel, MAGNITUDE, TALAPRO-2 (mCRPC)
🟢 Pancreas – POLO (gBRCA mPDAC maintenance)
💡 Mechanism: Exploits DNA repair defects → synthetic lethality
📈 Benefit: OS & PFS gains across tumor types
🔍 Trends: Expanding into combinations (IO, ADCs), early stages, and basket trials

💡 Main messages:
1️⃣ Synthetic lethality is now a validated therapeutic principle across tumor types.
2️⃣ HRR testing (BRCA1/2, ATM, PALB2…) should be integrated into routine work-up.
3️⃣ Maintenance strategies prolong disease control and delay chemo.
4️⃣ Combinations with IO & ADCs may expand benefit beyond BRCA+ disease.

🩺 Clinical implications:
✔ Test early → identify candidates before progression.
✔ Cross-tumor genomic panels are now standard in advanced disease.
✔ Watch for hematologic toxicity, fatigue & GI AEs — require proactive management.
@OncoAlert @APCCC
#PARPinhibitors #DNArepair #PrecisionOncology #OncoTwitter #Medicalwatch
https://t.co/Dln6IUYcpz

[CA: A Cancer Journal for Clinicians @CACancerJournal]

PARP inhibitors comprise a therapeutic class that targets PARP proteins involved in DNA repair. This #OpenAccess review of PARP inhibitor approvals emphasizes their efficacy across different cancers based on landmark phase 3 clinical trials.

🔗: https://t.co/gbBffsDw7D

[Dimitra R. Bakaloudi MD, MS, MPA @DRBakaloudiMD]

Feeling Incredible honored to receive the #JQTF award!🌟
Huge thanks to my mentors @PGrivasMDPhD & JWright - Always inspired 💯
Grateful to @BladderCancerUS for advancing research & advocacy. 🙏
Congrats @AmandaMyersMD @Anto_cigliola @alexzhuDO @DrAndrewKatims #BCANTT25 👏

[ASCO @ASCO]

Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO.

Learn more about FASCO distinction: https://t.co/AOfMsRxtH8

[Umang Swami, MD, MSCI, FASCO @umangtalking]

A very informative and detailed discussion on practice changing data and trial updates in bladder cancer by @PGrivasMDPhD #BestOfASCO 2025 in Boise! https://t.co/FRHlrbWoBM

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 https://t.co/AMqlUvlkNG and https://t.co/W8gO8lWxQo @PCFnews @urotoday @OncoAlert

[HemOnc Today @HemOncToday]

Real-world data show that only 30% to 40% of patients with the most common cancers receive NGS testing.

🗨️ “The ultimate goal would be for all patients to receive NGS testing earlier in their disease course," - @chadihcmd of @huntsmancancer told Healio.
https://t.co/bbHJH8q6TQ

[Yüksel Ürün @DrYukselUrun]

Metformin did not boost survival in metastatic hormone-sensitive prostate cancer.
It did ease ADT’s metabolic side effects.
Not a game-changer, but still some hope for patient quality of life. #Oncology
With very nice editorial by @ggebraelmd @chadihcmd and @neerajaiims
@TheLancetOncol @APCCC_Lugano @Silke_Gillessen @Prof_Nick_James @AlisonBirtle @scserendipity1 @AttardLab @drdjmath @mattsydes
https://t.co/oQ6oQBDFUO

https://t.co/OYHAI7JEkb

[The Lancet Oncology @TheLancetOncol]

✏️@neerajaiims, @chadihcmd, and Georges Gebrael discuss the STAMPEDE trial in their linked comment

See here: https://t.co/rBvevhrPmZ

[Chadi Hage Chehade @chadihcmd]

@PGrivasMDPhD @eaonc @PrECOGonc @NaomiHaas5 @MonikaJoshimd @JCensits @HutchPresident @nicoleflemingmd @Dr_AmerZeidan @BrainTumorDoc @shilpaonc @OncoAlert @TiansterZhang Congratulations Dr. Grivas!